Last Updated: 06/09/2024
Genetic diversity and molecular epidemiology of drug resistant molecular markers in P. falciparum at selected public health facilities
Objectives
- To determine genetic diversity of P. falciparum depending on msp1 and msp2.
- To assess prevalence of pfmdr1 and pfcrt allelic polymorphisms among the parasite population.
- To assess prevalence of pfdhfr and pfdhps allelic polymorphisms among the parasite population.
- To assess the prevalence and occurrence of mutations in kelch13 gene among the parasite population.
Adama Science and Technology University (ASTU), Ethiopia, Ethiopia
The genetic diversity of Plasmodium falciparum, the parasite responsible for severe malaria, plays a crucial role in its ability to develop drug resistance. Variations in its genetic makeup are significantly associated with drug-resistant genes. Despite the initial success of chloroquine and Sulfadoxine-Pyrimethamine as first-line treatments, widespread resistance led to their abandonment. Currently, artemisinin-based combination therapies are the first-line treatment for uncomplicated falciparum malaria, but resistance is threatening their effectiveness. Thus, investigating the current status of drug resistance in Plasmodium falciparum populations, focusing on the prevalence of wild-type and resistant strains, including artemisinin-based resistant strains is crucial. By analyzing mutations in genes such as mdr1, crt, dhfr, dhps, andkelch13, this research aims to determine whether wild-type parasites have reversed or if resistant strains are dominating, providing critical insights into the dynamics of drug resistance in P.falciparum populations. The findings of this study will inform treatment strategies and guide the development of effective interventions to combat malaria.
Jul 2022 — Jul 2025
$1,143
Related Resources
